Esophageal Cancer: An Updated Surveillance Epidemiology and End Results Database Analysis

Then, Eric O.; Lopez, Michell; Saleem, Saad; Gayam, Vijay; Sunkara, Tagore; Culliford, Andrea; Gaduputi, Vinaya

doi:10.14740/wjon1254

Cited by 198 publications

(158 citation statements)

References 39 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…The widest range of variation was in squamous tumors (Figure 9 – red dashed line). Thus, in an American study [ 29 ] and a Swedish study [ 25 ], M/F ratio had the lowest value, namely 1.9. The highest ratio was of 21.3 and was reported by a Chinese group of researchers [ 33 ].…”

Section: ⧉ Discussionmentioning

confidence: 99%

Clinical–morphological profiles of esophageal carcinoma’s main types

Cameniță

Demetrian

Pleşea

et al. 2020

Rom J Morphol Embryol

View full text Add to dashboard Cite

show abstract

Section: ⧉ Discussionmentioning

confidence: 99%

Clinical–morphological profiles of esophageal carcinoma’s main types

Cameniță

Demetrian

Pleşea

et al. 2020

Rom J Morphol Embryol

View full text Add to dashboard Cite

show abstract

“…The sixth leading cause of cancer-related death and the eighth most common cancer in the world, esophageal cancer is associated with a 5-year survival rate of less than 25% [39]. While endoscopy, CT, and MRI have conventionally been used to examine patients with esophageal cancer, the relatively new technique of PET has been increasingly used for the diagnosis, differential diagnosis, and clinical staging of patients with esophageal cancer.…”

Section: Discussionmentioning

confidence: 99%

Using 18F-FDG PET/CT to Predict Esophageal Cancer Survival: A Meta-analysis

Wang

Song

2020

Preprint

View full text Add to dashboard Cite

Background: This study aimed to explore whether metabolic responses to positron emission tomography/computed tomography (PET/CT) collected before, during, or after the treatment can predict the long-term survival rate of patients with esophageal cancer.Main body: We searched for the following indices in articles listed in English and Chinese literature databases: the maximum standard uptake value (SUVmax), mean standard uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG). If their values exceeded the thresholds, we defined them as responders; if they did not, we defined them as non-responders. We then performed a meta-analysis by extracting the hazard ratio (HR) and 95% confidence interval (95% CI) from each report to predict whether the status of responder or non-responder had an impact on prognosis.We identified 34 articles with a combined sample size of 2794 patients. HRs and 95% CIs were measured as follows: SUVmax = 1.15 (0.98-1.35), MTV = 3.45 (0.78-15.25), TLG = 1.04 (1.02-1.07), and SUVmean = 1.85 (1.33-2.57) (before treatment); ΔSUVmax = 1.22 (1.06-1.39), Δ MTV = 1.07 (0.54-2.15), and ΔTLG = 1.09 (0.59-2.02) (during treatment); and SUVmax = 1.13 (1.05-1.22) and TLG = 1.05 (1.02-1.09) (after treatment). The results showed that the overall survival of the patients with low SUV (MTV, TLG) values was significantly higher than that of the patients with high SUV (MTV, TLG) values.Conclusions: This meta-analysis shows that the prognoses of patients with PET metabolic responses are significantly better than those of non-responders. Our findings may help inform the clinical treatment and prediction of the prognoses of patients with esophageal cancer.

show abstract

“…Esophageal carcinoma is one of the most common malignant tumors. It ranks the seventh in incidence and sixth in mortality all over the world [ 1 ]. In China, esophageal carcinoma is the leading cause of cancer death [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Targeting SNHG3/miR-186-5p reverses the increased m6A level caused by platinum treatment through regulating METTL3 in esophageal cancer

et al. 2021

View full text Add to dashboard Cite

Background Platinum-based chemotherapy is a mainstay for treating esophageal cancer patients. In this manuscript, we have provided clues for influence of platinum on overall m6A level and further investigated the potential regulatory mechanism. Methods qRT-PCR was used to measure SNHG3 and miR-186-5p expression; ELISA and western blot were used to measure the expression of METTL3. CCK8 was used to measure the cell proliferation rate. Caspase 3/7 activity was used to measure the apoptosis rate. Dual luciferase reporter gene assay and RNA pull down assay were used to investigate the potential crosstalk between miR-186-5p and SNHG3; and miR-186-5p and METTL3. Results m6A level was increased when treated with platinum (CDDP, CPB and L-OHP). Besides, SNHG3 expression was induced and miR-186-5p expression was suppressed by platinum. Furthermore, SNHG3 could promote the m6A level, however miR-186-5p inhibited the m6A level through targeting METTL3. SNHG3 interacts with miR-186-5p to negatively regulate the expression of miR-186-5p; and miR-186-5p might bind to the 3′UTR of METTL3 to regulate its expression. Conclusion Platinum can increase the overall m6A level of esophageal cancer. SNHG3/miR-186-5p, induced by platinum, was involved in regulating m6A level by targeting METTL3. Our manuscript has provided clues that regulating m6A level might be a novel way to enhance the platinum efficacy.

show abstract

Esophageal Cancer: An Updated Surveillance Epidemiology and End Results Database Analysis

Cited by 198 publications

References 39 publications

Clinical–morphological profiles of esophageal carcinoma’s main types

Clinical–morphological profiles of esophageal carcinoma’s main types

Using 18F-FDG PET/CT to Predict Esophageal Cancer Survival: A Meta-analysis

Targeting SNHG3/miR-186-5p reverses the increased m6A level caused by platinum treatment through regulating METTL3 in esophageal cancer

Contact Info

Product

Resources

About